First virtual clinical trial examines two promising Alzheimer’s drugs
A first-of-its-kind simulated clinical trial has modelled long-term health outcomes for two key Alzheimer’s drugs to determine optimal treatments.
List view / Grid view
A first-of-its-kind simulated clinical trial has modelled long-term health outcomes for two key Alzheimer’s drugs to determine optimal treatments.
The trial will assess the efficacy of a two week regimen of the FDA-approved antibiotic dalbavancin in treating 100 patients with Staphylococcus aureus bacteremia.
A new vaccine platform using self-assembling peptide nanofibres tagged with antigens has been tested successfully in mice, eliciting a strong immune response.
Drug that strengthens blood vessels allows antibiotics to infiltrate tuberculosis granulomas in mice...
13 June 2012 | By Merck
New data from two pivotal Phase III trials...
29 May 2009 | By
1. How significantly do you feel the Drug Discovery Process has benefited from the application of High Content Analysis techniques? Anthony Davies: Since the mid 1990's High-content analysis (HCA) has primarily been used in the later stages of the pre-clinical drug discovery process. However, as HCA techniques have developed and…